CYP2D6 phenotyping in clinical practice: serum or urine dextromethorphan/dextrorphan metabolic ratio?

JUŘICA, Jan, Richard BARTEČEK, Eva PINDUROVÁ, Ondřej ZENDULKA, Tomáš KAŠPÁREK and Alexandra ŠULCOVÁ. CYP2D6 phenotyping in clinical practice: serum or urine dextromethorphan/dextrorphan metabolic ratio? In Andrew W. Munro, David Leys. 17th International Conference on Cytochrome P450. Bologna: Medimond, 2011, p. 39-42. ISBN 978-88-7587-616-6.

Basic information

• Original name: CYP2D6 phenotyping in clinical practice: serum or urine dextromethorphan/dextrorphan metabolic ratio?
• Name in Czech: Stanovení fenotypu CYP2D6 v praxi: metabolický poměr dextrometorfan/dextrorfan v séru nebo moči?
• Authors: JUŘICA, Jan (203 Czech Republic, guarantor, belonging to the institution), Richard BARTEČEK (203 Czech Republic, belonging to the institution), Eva PINDUROVÁ (203 Czech Republic, belonging to the institution), Ondřej ZENDULKA (203 Czech Republic, belonging to the institution), Tomáš KAŠPÁREK (203 Czech Republic, belonging to the institution) and Alexandra ŠULCOVÁ (203 Czech Republic, belonging to the institution).
• Edition: Bologna, 17th International Conference on Cytochrome P450, p. 39-42, 4 pp. 2011.
• Publisher: Medimond

Other information

• Original language: English
• Type of outcome: Proceedings paper
• Field of Study: 30104 Pharmacology and pharmacy
• Country of publisher: United Kingdom of Great Britain and Northern Ireland
• Confidentiality degree: is not subject to a state or trade secret
• RIV identification code: RIV/00216224:14110/11:00056989
• Organization unit: Faculty of Medicine
• ISBN: 978-88-7587-616-6
• UT WoS: 000304083600007
• Keywords (in Czech): CYP2D6; fenotyp
• Keywords in English: CYP2D6; phenotype

Abstract

The aim of this work was to elucidate if CYP2D6 phenotyping by evaluation of molar dextromethorphan to dextrorphan metabolic ratio (MRDEM/DOR) in serum has the usability and reliability as the assessment of MRDEM/DOR in urine. We measured MRDEM/DOR in serum and CYP2D6 genotype in 51 drug-naive patients and investigated cut-off value for discrimination of poor metabolizers from extensive and intermediate ones. The correlation of serum MRDEM/DOR with urine MRDEM/DOR in 30 healthy volunteers was analysed in parallel.

Links

• NS9676, research and development project: Name: Vliv farmakogenetických a farmakokinetických faktorů na účinnost a bezpečnost terapie prvních epizod schizofrenie

Investor: Ministry of Health of the CR